MaxCyte (MXCT) Competitors $1.43 -0.61 (-29.90%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-0.70%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. IIIV, FVRR, PRSU, RSKD, CARS, PSFE, NRDS, MEG, NEO, and UXINShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include i3 Verticals (IIIV), Fiverr International (FVRR), Pursuit Attractions and Hospitality (PRSU), Riskified (RSKD), Cars.com (CARS), Paysafe (PSFE), NerdWallet (NRDS), Montrose Environmental Group (MEG), NeoGenomics (NEO), and Uxin (UXIN). These companies are all part of the "business services" industry. MaxCyte vs. Its Competitors i3 Verticals Fiverr International Pursuit Attractions and Hospitality Riskified Cars.com Paysafe NerdWallet Montrose Environmental Group NeoGenomics Uxin MaxCyte (NASDAQ:MXCT) and i3 Verticals (NASDAQ:IIIV) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Do analysts prefer MXCT or IIIV? MaxCyte presently has a consensus target price of $7.00, suggesting a potential upside of 389.51%. i3 Verticals has a consensus target price of $29.57, suggesting a potential upside of 3.76%. Given MaxCyte's higher probable upside, equities analysts plainly believe MaxCyte is more favorable than i3 Verticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75i3 Verticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has higher earnings and valuation, MXCT or IIIV? i3 Verticals has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than i3 Verticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxCyte$37.68M4.04-$41.06M-$0.43-3.33i3 Verticals$229.92M4.12$113.34M$4.406.48 Which has more risk & volatility, MXCT or IIIV? MaxCyte has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, i3 Verticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Do institutionals & insiders have more ownership in MXCT or IIIV? 68.8% of MaxCyte shares are held by institutional investors. Comparatively, 84.2% of i3 Verticals shares are held by institutional investors. 3.3% of MaxCyte shares are held by company insiders. Comparatively, 59.1% of i3 Verticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is MXCT or IIIV more profitable? i3 Verticals has a net margin of 46.46% compared to MaxCyte's net margin of -125.22%. i3 Verticals' return on equity of 3.15% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets MaxCyte-125.22% -21.70% -18.71% i3 Verticals 46.46%3.15%2.00% Does the media prefer MXCT or IIIV? In the previous week, MaxCyte had 3 more articles in the media than i3 Verticals. MarketBeat recorded 7 mentions for MaxCyte and 4 mentions for i3 Verticals. i3 Verticals' average media sentiment score of 0.84 beat MaxCyte's score of -0.21 indicating that i3 Verticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral i3 Verticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summaryi3 Verticals beats MaxCyte on 15 of the 17 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$217.09M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.18%P/E Ratio-3.3317.9729.8725.14Price / Sales4.04262.19422.9397.17Price / CashN/A41.8335.9458.58Price / Book0.737.238.105.59Net Income-$41.06M-$54.43M$3.26B$265.48M7 Day Performance-29.90%0.22%0.64%1.22%1 Month Performance-35.59%5.59%2.42%0.39%1 Year Performance-65.79%9.98%27.60%23.47% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte2.4096 of 5 stars$1.43-29.9%$7.00+389.5%-65.0%$217.09M$37.68M-3.3380Earnings ReportAnalyst DowngradeGap DownHigh Trading VolumeIIIVi3 Verticals3.8116 of 5 stars$28.92+0.8%$29.57+2.3%+20.6%$952.99M$229.92M6.571,480News CoveragePositive NewsFVRRFiverr International3.2384 of 5 stars$25.32-1.7%$36.00+42.2%+1.6%$923.70M$391.48M53.87790PRSUPursuit Attractions and Hospitality1.2393 of 5 stars$31.54-0.6%$29.67-5.9%N/A$896.28M$366.49M2.561,500News CoverageEarnings ReportGap UpRSKDRiskified1.1363 of 5 stars$5.41-0.1%$6.03+11.6%-11.2%$872.14M$327.52M-24.57780News CoverageCARSCars.com3.5911 of 5 stars$13.39-0.2%$18.30+36.7%-33.7%$852.55M$718M19.691,800News CoveragePSFEPaysafe3.0794 of 5 stars$13.24-3.7%$16.95+28.0%-37.9%$823.46M$1.70B-662.003,300Upcoming EarningsNRDSNerdWallet1.9155 of 5 stars$10.93-0.3%$15.00+37.2%+4.0%$816.66M$687.60M28.03770News CoveragePositive NewsEarnings ReportMEGMontrose Environmental Group3.1388 of 5 stars$23.27-0.7%$31.80+36.7%-16.2%$812.52M$696.40M-10.033,410Gap UpNEONeoGenomics4.2624 of 5 stars$6.46+2.7%$13.83+114.1%-63.7%$809.49M$660.57M-10.592,200High Trading VolumeUXINUxin0.5451 of 5 stars$3.99-5.9%N/A+134.4%$797.06M$190.40M-19.95810High Trading Volume Related Companies and Tools Related Companies i3 Verticals Alternatives Fiverr International Alternatives Pursuit Attractions and Hospitality Alternatives Riskified Alternatives Cars.com Alternatives Paysafe Alternatives NerdWallet Alternatives Montrose Environmental Group Alternatives NeoGenomics Alternatives Uxin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
